Clover Health Corp (CLOV) shares surged in pre-market trading on October 11, 2024, following positive developments related to its Medicare Advantage plans and benchmark rates.
The company's Medicare Advantage PPO plans earned a coveted 4-star rating for the 2025 plan year, outperforming larger rivals like Humana. This high rating is expected to boost Clover Health's ability to attract and retain Medicare Advantage enrollees, a key driver of growth for the company.
Furthermore, Clover Health announced that due to its PPO contract receiving a 4.0-star rating, it expects a general 5% increase in benchmark rates for the 2026 payment year. This increase in benchmark rates is expected to translate into higher revenues for the company, providing a direct financial benefit from its strong quality rating.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。